Does the metastatic lymph node ratio influence the disease-free survival of patients with breast cancer: Single-center experiences

MakaleYalnız künye
  • SDG 3 · Sağlık ve Kaliteli Yaşam

Özet

Background: Axillary lymph nodes (ALNs) are the most important prognostic factor for survival in breast cancer. Pathological evaluation can affect the number of involved lymph nodes. In the current study, we evaluated whether the metastatic lymph node ratio (n ratio) is important in predicting disease-free survival (DFS) for breast cancer patients. Material and Methods: From 802 breast cancer cases, 427 patients with ALN metastasis were analyzed retrospectively. The n ratio was categorized as n ratio 1 (1-10%), n ratio 2 (10.01-50%) and n ratio 3 (>50%). DFS was established according to the Kaplan-Meier method. Predicting risk factors for relapse were analyzed using the Cox proportional hazards model. Results: The n ratio was significantly higher in breast cancer patients with advanced pathologic pT, pN and clinical stage, undifferentiated histology, lymphovascular and extracapsular invasion, more resected ALNs and positive progesterone receptor. In the univariate analysis, multicentricity, necrosis, grade, pN stage, estrogen receptor and progesterone receptor positivity, trastuzumab and neoadjuvant chemotherapy usage, the presence of inflammatory breast cancer and n ratio were found to be important factors in predicting DFS. Multivariate analysis indicated that multicentricity, neoadjuvant chemotherapy, trastuzumab usage and n ratio were significantly associated with prognosis. Conclusions: The n ratio is inexpensive, easily available and a simple prognostic factor for breast cancer patients with positive ALNs.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/gumushane/15512Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1159/000320162Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorOven Ustaalioglu, Bala Basak
dc.contributor.authorBilici, Ahmet
dc.contributor.authorKefeli, Umut
dc.contributor.authorŞeker, Mesut
dc.contributor.authorYildirim, Emre
dc.contributor.authorSalepci, Taflan
dc.contributor.authorOncel, Mustafa
dc.contributor.authorKement, Metin
dc.contributor.authorGumus, Mahmut
dc.date.accessioned2026-10-22T10:24:07.686678026Z
dc.date.available2026-10-22T10:24:07.686678026Z
dc.date.issued2010
dc.description.abstractBackground: Axillary lymph nodes (ALNs) are the most important prognostic factor for survival in breast cancer. Pathological evaluation can affect the number of involved lymph nodes. In the current study, we evaluated whether the metastatic lymph node ratio (n ratio) is important in predicting disease-free survival (DFS) for breast cancer patients. Material and Methods: From 802 breast cancer cases, 427 patients with ALN metastasis were analyzed retrospectively. The n ratio was categorized as n ratio 1 (1-10%), n ratio 2 (10.01-50%) and n ratio 3 (>50%). DFS was established according to the Kaplan-Meier method. Predicting risk factors for relapse were analyzed using the Cox proportional hazards model. Results: The n ratio was significantly higher in breast cancer patients with advanced pathologic pT, pN and clinical stage, undifferentiated histology, lymphovascular and extracapsular invasion, more resected ALNs and positive progesterone receptor. In the univariate analysis, multicentricity, necrosis, grade, pN stage, estrogen receptor and progesterone receptor positivity, trastuzumab and neoadjuvant chemotherapy usage, the presence of inflammatory breast cancer and n ratio were found to be important factors in predicting DFS. Multivariate analysis indicated that multicentricity, neoadjuvant chemotherapy, trastuzumab usage and n ratio were significantly associated with prognosis. Conclusions: The n ratio is inexpensive, easily available and a simple prognostic factor for breast cancer patients with positive ALNs.
dc.identifier.doi10.1159/000320162
dc.identifier.endpage111
dc.identifier.issn0030-2414
dc.identifier.issue1-2
dc.identifier.pmid21088436
dc.identifier.scopus2-s2.0-78349294610
dc.identifier.startpage105
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/gumushane/15512
dc.identifier.volume79
dc.identifier.wosWOS:000285584300015
dc.language.isoen
dc.publisherKARGER
dc.relation.ispartofOncology
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBreast cancer
dc.subjectDisease-free survival
dc.subjectLymph node ratio
dc.subject.classificationOncology
dc.subject.otherAdult
dc.subject.otherAged
dc.subject.otherAged, 80 and over
dc.subject.otherAntineoplastic Combined Chemotherapy Protocols
dc.subject.otherAxilla
dc.subject.otherBreast Neoplasms
dc.subject.otherDisease-Free Survival
dc.subject.otherFemale
dc.subject.otherHumans
dc.subject.otherInflammatory Breast Neoplasms
dc.subject.otherKaplan-Meier Estimate
dc.subject.otherLymph Node Excision
dc.subject.otherLymph Nodes
dc.subject.otherLymphatic Metastasis
dc.subject.otherMiddle Aged
dc.subject.otherNecrosis
dc.subject.otherNeoadjuvant Therapy
dc.subject.otherNeoplasm Invasiveness
dc.subject.otherNeoplasm Staging
dc.subject.otherPredictive Value of Tests
dc.subject.otherPrognosis
dc.subject.otherProportional Hazards Models
dc.subject.otherRetrospective Studies
dc.subject.otherRisk Assessment
dc.subject.otherRisk Factors
dc.subject.otherTumor Markers, Biological
dc.subject.otherestrogen receptor
dc.subject.otherprogesterone receptor
dc.subject.othertrastuzumab
dc.subject.otherarticle
dc.subject.otheraxillary lymph node
dc.subject.otherbreast cancer
dc.subject.othercancer adjuvant therapy
dc.subject.othercancer grading
dc.subject.othercancer invasion
dc.subject.othercancer relapse
dc.subject.othercancer staging
dc.subject.otherdisease free survival
dc.subject.otherhistopathology
dc.subject.otherhuman
dc.subject.otherlymph node metastasis
dc.subject.othermajor clinical study
dc.subject.otherprediction
dc.subject.otherpriority journal
dc.subject.otherretrospective study
dc.subject.otherrisk factor
dc.titleDoes the metastatic lymph node ratio influence the disease-free survival of patients with breast cancer: Single-center experiences
dc.typeArticle
dspace.entity.typePublication
rdl.citation.openalex11
rdl.citation.scopus8
rdl.citation.wos7
rdl.oa.statusclosed
rdl.sdgSDG03
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)